Dr Tolaney talks to ecancer at ASCO 2025 about data she presented from the phase 3 DESTINY-Breast09 clinical trial.

This found that the combination of trastuzumab deruxtecan with pertuzumab can delay cancer growth for longer than the current standard of care in people with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer.

For patients who received trastuzumab deruxtecan and pertuzumab, about 85% had their cancer shrink or disappear compared to 78.6% of those in the docetaxel, trastuzumab and pertuzumab (THP) group. About 15% of patients who responded to treatment with trastuzumab deruxtecan and pertuzumab had no signs of cancer in response to the treatment vs. 8.5% in the THP group.

The study continues.

Read the related news story here.